Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Renal Cancer Clinical Trials

13 recruiting trials for Renal Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
13
Total Trials
13
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06357416

The Man Van Project

National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the...

Sponsor: Royal Marsden NHS Foundation TrustEnrolling: 40001 location
RECRUITINGNCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible...

Sponsor: Institut Claudius RegaudEnrolling: 4501 location
RECRUITINGNCT02087852

Kidney Cancer DNA Registry

This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 7507 locations
RECRUITINGPhase 2NCT06962787

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 2601 location
RECRUITINGNCT07299357

Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer:...

The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are...

Sponsor: Istituto Clinico HumanitasEnrolling: 532 locations
RECRUITINGNCT07037589

Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?

This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy...

Sponsor: Vastra Gotaland RegionEnrolling: 3001 location
RECRUITINGNCT06863857

Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer

To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 502 locations
RECRUITINGNCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and...

Sponsor: RenJi HospitalEnrolling: 3001 location
RECRUITINGNCT06147349

Kidney Cancer Observational Protocol

The aim of this observational study is to gather pre and post surgery clinical data belonging to patients who underwent radical or partial nephrectomy and to evaluate the impact...

Sponsor: IRCCS San RaffaeleEnrolling: 25001 location
RECRUITINGPhase 2NCT05842044

NSAID Use After Robotic Partial Nephrectomy

The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after...

Sponsor: University of MiamiEnrolling: 1101 location
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 2856 locations
RECRUITINGPhase 1NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid...

Sponsor: Nuvectis Pharma, Inc.Enrolling: 14012 locations
RECRUITINGNCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 3972 locations

Frequently Asked Questions

There are currently 13 clinical trials for Renal Cancer, with 13 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Renal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Renal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.